Status:
RECRUITING
Ivabradine in Cirrhotic Cardiomyopathy
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Cirrhotic Cardiomyopathy
Left Ventricular Dysfunction
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
A total of 130 patients with liver cirrhosis who fulfill the criteria of the study, and who have been found to have left ventricular diastolic dysfunction on a screening 2D echocardiography, will then...
Detailed Description
The investigators have already demonstrated the role of targeted heart rate reduction in the management of LVDD in cirrhosis, but the previous study could not demonstrate the role of ivabradine alone ...
Eligibility Criteria
Inclusion
- Age range of 18-65 years
- Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings,
- LV diastolic dysfunction on 2D echocardiography
Exclusion
- Chronic renal disease
- Patient already on beta blocker
- Pregnancy and peripartum cardiomyopathy
- Hypertension
- Coronary artery disease
- Valvular heart disease
- Sick sinus syndrome/ Pacemaker
- Cardiac rhythm disorder
- Hypothyroidism
- Hyperthyroidism
- Portal vein thrombosis
- Transjugular intrahepatic porto systemic shunt (TIPS) insertion
- Hepatocellular carcinoma
- Anemia Hb \< 8gm/dl in females, and \< 9 gm/dl in males
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04111133
Start Date
January 1 2020
End Date
December 1 2024
Last Update
February 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Postgraduate Institute of Medical Education and Research
Chandigarh, Choose Any State/Province, India, 160012